Technology Commercialization Office

Showing 36 result(s) for "Healthcare Portfolios"

The Need The most abundant neurotransmitter in the central nervous system is glutamate. The role of this neurotransmitter is to send excitiatory signals to aid in modulation of normal brain function. However, abnormal release of glutamate can overstimulate the neuronal system, resulting in excitoxicty. Glutamate-mediated excitoxicity is involved in many neurological disorders, such as epilepsy, stroke, Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). Currently available drugs for the prevention of

Novel strategy to improve efficiency and specificity of tumor treatment via combinative use of a split & splice protein toxin and oncolytic virus.

A device to discourage IV-drug-abusing patients from self-accessing their IV ports while in the hospital

A novel method to increase vaccine effectiveness for TB

Realistic immunohistochemical stained tissue section databases for training, certification, and machine standards.

A novel therapeutic strategy to sensitize Hepatocellular Carcinoma tumors to a multikinase inhibitor for advanced stage treatment.

Encoding strategy for improvement of speech understanding in a noisy environment for audiotory prosthetic devices.

Engineered calmodulin-based therapeutics for the treatment of cardiovascular diseases.

Novel lipid-based nanoparticles that utilize a surfactant to improve self-assembly and stability. Finalized particles can be used for delivery of nucleic acids such as oligonucleotides and plasmid DNA.

A diagnostic to provide more swift and reliant detection of Alzheimer's disease by monitoring the chemical modification of tau proteins in bodily fluids.